carmustine has been researched along with Cancer of Prostate in 15 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy." | 3.75 | Chemotherapy of hormonally unresponsive prostatic carcinoma. ( deKernion, JB; Lindner, A, 1984) |
| "The efficacy of chemotherapy for prostatic cancer is difficult to evaluate owing to the low incidence of measurable indicator lesions and the resulting need for indirect response criteria." | 2.37 | Chemotherapy principles in the treatment of prostatic cancer. ( Könyves, I; Müntzing, J; Rozencweig, M, 1984) |
| "Stereotactic body radiotherapy for prostate cancer using CyberKnife with circular cone requires a long treatment time." | 1.91 | Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy. ( Akino, Y; Mabuchi, N; Masai, N; Ogawa, K; Oh, RJ; Shiomi, H, 2023) |
| "Prostate carcinoma is the most commonly occurring malignancy in men." | 1.32 | 2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways. ( Do, P; Huynh, H; Nguyen, TH; Panasci, L, 2004) |
| "Carmustine (BCNU) is an anticancer agent and a putative inhibitor of Gly-I, while beta-glucan is a unique, nontoxic polysaccharide extracted from maitake mushrooms." | 1.31 | Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. ( Aynehchi, S; Choudhury, MS; Drinis, S; Finkelstein, MP; Konno, S; Samadi, AA; Tazaki, H, 2002) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | 1.26 | Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akino, Y | 1 |
| Shiomi, H | 1 |
| Mabuchi, N | 1 |
| Masai, N | 1 |
| Oh, RJ | 1 |
| Ogawa, K | 1 |
| Thamilselvan, V | 1 |
| Menon, M | 1 |
| Stein, GS | 1 |
| Valeriote, F | 1 |
| Thamilselvan, S | 1 |
| Stankiewicz-Kranc, A | 1 |
| Miltyk, W | 1 |
| Skrzydlewska, E | 1 |
| Finkelstein, MP | 1 |
| Aynehchi, S | 1 |
| Samadi, AA | 1 |
| Drinis, S | 1 |
| Choudhury, MS | 1 |
| Tazaki, H | 1 |
| Konno, S | 1 |
| Qiu, Q | 1 |
| Dudouit, F | 1 |
| Banerjee, R | 1 |
| McNamee, JP | 1 |
| Jean-Claude, BJ | 1 |
| Huynh, H | 1 |
| Nguyen, TH | 1 |
| Panasci, L | 1 |
| Do, P | 1 |
| Heim, ME | 1 |
| Eberwein, S | 1 |
| Georgi, M | 1 |
| deKernion, JB | 1 |
| Lindner, A | 1 |
| Könyves, I | 1 |
| Müntzing, J | 1 |
| Rozencweig, M | 1 |
| Stein, BS | 1 |
| Kendall, AR | 1 |
| Drago, JR | 3 |
| Worgul, TJ | 2 |
| Gallagher, C | 1 |
| Goldman, LB | 1 |
| Worgul, T | 1 |
| Gershwin, ME | 1 |
| Presant, CA | 1 |
| Van Amburg, A | 1 |
| Klahr, C | 1 |
| Metter, GE | 1 |
| Dolan, ME | 1 |
| Pegg, AE | 1 |
| Biser, ND | 1 |
| Moschel, RC | 1 |
| English, HF | 1 |
3 reviews available for carmustine and Cancer of Prostate
| Article | Year |
|---|---|
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
Chemotherapy principles in the treatment of prostatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Castration; Cisplatin; Cyclopho | 1984 |
Malignant melanoma of the genitourinary tract.
Topics: Adrenal Gland Neoplasms; Adult; Aged; BCG Vaccine; Carmustine; Combined Modality Therapy; Dacarbazin | 1984 |
1 trial available for carmustine and Cancer of Prostate
| Article | Year |
|---|---|
Chemotherapy of hormonally unresponsive prostatic carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Cispla | 1984 |
12 other studies available for carmustine and Cancer of Prostate
| Article | Year |
|---|---|
Optimization of Fluence Map for CyberKnife Raster Scanning Intensity Modulated Radiotherapy.
Topics: Carmustine; Etoposide; Humans; Male; Prostatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Radioth | 2023 |
Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells.
Topics: Apoptosis; Carmustine; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Male; MAP Kinas | 2017 |
Comparison of influence of carmustine and new proline analog of nitrosourea on antioxidant system in breast carcinoma cells (MCF-7).
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe | 2010 |
Chemosensitization of carmustine with maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I.
Topics: Agaricales; Androgens; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 2002 |
Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.
Topics: Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA Damage; ErbB Recep | 2004 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carmustine; Cell Cycle; Cell Cycle Proteins; Cell Divisio | 2004 |
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe | 1983 |
Castration--chemotherapy treatment of prostate cancer model.
Topics: Animals; Carmustine; Castration; Cell Transformation, Neoplastic; Cisplatin; Cyclophosphamide; Disea | 1981 |
Therapy for Nb rat tumor transplanted in athymic mice.
Topics: Adenocarcinoma; Androgens; Animals; Carmustine; Dactinomycin; Male; Mice; Mice, Nude; Neoplasm Metas | 1981 |
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, | 1981 |
Chemotherapy of advanced prostatic cancer with adriamycin, BCNU, and cyclophosphamide.
Topics: Carmustine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Thera | 1980 |
Effect of O6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1-nitrosourea in the Dunning R3327G model of prostatic cancer.
Topics: Animals; Carmustine; Drug Interactions; Guanine; Kidney; Liver; Male; Methyltransferases; O(6)-Methy | 1993 |